China's battle against diabetes has reached a pivotal moment with groundbreaking advancements in stem cell therapy. With over 140 million adults living with the disease—representing nearly 12% of the adult population—the country faces one of the world's largest diabetes epidemics. Traditional treatments like insulin injections manage symptoms but fail to address the root cause: the loss of insulin-producing beta cells in the pancreas. Recent clinical successes from university-affiliated hospitals have demonstrated that stem cell-derived islet cells can restore the body's natural insulin production, offering hope for a functional cure.
Naval Medical University Leads Type 2 Diabetes Breakthrough
Researchers at Shanghai Changzheng Hospital, affiliated with Naval Medical University (formerly Second Military Medical University), achieved a world-first in 2024. Led by Prof. Yin Hao, the team treated a 59-year-old man who had been insulin-dependent for 25 years due to end-stage type 2 diabetes. They isolated endoderm stem cells (EnSCs) from his peripheral blood, differentiated them in vitro into functional islet tissue (E-islets) through pancreatic progenitors and endocrine progenitors, and transplanted approximately 1.2 million islet equivalents (IEQs) via the portal vein.
The process mimics natural pancreatic development: EnSCs were cultured under GMP conditions, achieving viability over 95% and glucose-stimulated insulin secretion comparable to cadaveric islets. Preclinical tests in diabetic mice and monkeys confirmed efficacy and low immunogenicity. Post-transplant, the patient's fasting C-peptide levels tripled to 0.68 nmol/L, HbA1c dropped to 4.6%, and time-in-range reached 99%. Remarkably, he discontinued insulin after 11 weeks and all medications after a year, with no serious adverse events over 116 weeks.
Nankai University and Peking University Advance Type 1 Treatment
In parallel, a team from Tianjin First Central Hospital (Nankai University School of Medicine) and Peking University College of Life Sciences reported success in type 1 diabetes. Prof. Shusen Wang and Prof. Hongkui Deng reprogrammed adipose-derived mesenchymal stromal cells from a 25-year-old woman's fat into chemically induced pluripotent stem cells (CiPSCs) using small molecules, avoiding viral vectors for safety. These CiPSCs were differentiated into islet-like cells (CiPSC-islets) with 60% beta cells.
Transplanted under the abdominal rectus sheath (1.5 million IEQs), the graft enabled insulin independence by day 75. HbA1c fell below 5.7%, C-peptide rose to 721 pmol/L, and no tumors formed over a year. Rigorous safety checks, including whole-genome sequencing and teratoma assays in mice/primates, confirmed no off-target mutations or pluripotency residuals. This autologous approach sidesteps immune rejection, a major hurdle in allogeneic transplants.Details in the Cell study.
Step-by-Step: How Stem Cells Become Insulin Factories
Stem cell therapy for diabetes involves precise reprogramming. First, adult cells (blood or fat) are converted to pluripotent stem cells capable of any cell type. For EnSCs (type 2 case), blood monocytes are induced into definitive endoderm. CiPSCs use chemicals like CHIR99021 to activate Wnt signaling.
- Stage 1: Pluripotent stem cells form pancreatic progenitors (PDX1+, NKX6.1+).
- Stage 2: Endocrine progenitors emerge (NEUROG3+).
- Stage 3: Maturation into beta (INS+), alpha (GCG+), delta (SST+) cells in 3D aggregates.
- Quality Control: Glucose-stimulated insulin secretion (GSIS) index >1.3, viability >95%, no pluripotency markers.
- Transplant: Minimally invasive sites like rectus sheath or portal vein promote vascularization.
Chinese universities excel here, with Peking University's Deng lab pioneering chemical reprogramming since 2013, reducing cancer risk.
Safety Profile and Long-Term Monitoring
Safety is paramount. Both trials reported no tumorigenesis; grafts monitored via MRI/ultrasound showed stable vascularized clusters without expansion. Immunosuppression minimized (basiliximab induction, tacrolimus maintenance) due to autologous nature. C-peptide assays and mixed-meal tolerance tests verified function. Limitations include small cohorts (n=1-3), short follow-up (1-2 years), and need for larger phase II/III trials. No off-target effects or infections noted, but long-term graft survival remains key.Cell Discovery details the type 2 protocol.
Chinese Higher Education's Role in Biotech Innovation
These advances stem from China's investment in university research. Naval Medical University integrates military precision with stem cell expertise, while Nankai and Peking Universities lead pluripotent cell tech. National funding via NSFC and 'Double First-Class' initiatives supports GMP facilities. Shanghai's biotech cluster, home to CAS institutes, fosters collaborations. Impacts include training PhD students in regenerative medicine, attracting global talent, and positioning China as a stem cell leader—over 47 diabetes trials worldwide, China leads with 33%.
Career opportunities abound in /research-jobs at these institutions.
Stakeholder Perspectives: Patients, Experts, Policymakers
Patients report life-changing freedom from injections. Prof. Deng notes, "Autologous CiPSCs eliminate rejection risks." International experts like Doug Melton (Harvard) praise scalability. China's NHC fast-tracks trials, eyeing commercialization. Challenges: high costs (~$500K), manufacturing scale-up. Balanced views highlight ethics of editing patient cells.
Broader Implications for Diabetes Management
Restoring endogenous insulin curbs complications like neuropathy (affects 50% Chinese diabetics). Economic savings: diabetes costs China $100B+ yearly. University spin-offs could democratize access. For type 1 (5-10% cases), this rivals Vertex's VX-880 trials.
Challenges, Ethical Considerations, and Next Steps
- Scalability: GMP production for millions.
- Ethics: Autologous avoids donor issues but requires oversight.
- Trials: Phase I ongoing (ChiCTR2300072200); Peking U plans 10-patient study.
Universities like Tsinghua invest in AI-optimized differentiation.
Global Context and Chinese Leadership
While US (Vertex, Sana) advances allogeneic islets, China's autologous focus excels for personalization. Collaborations with CRISPR Therapeutics eyed. Policy: 'Healthy China 2030' prioritizes stem cells.
Future Outlook: Toward Widespread Availability
By 2030, experts predict routine use if trials succeed. Chinese universities train next-gen researchers; explore /higher-ed-jobs for opportunities. Actionable: monitor trials, support funding. This heralds a post-insulin era.